Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
PurposeThe introduction of ligands targeting prostate-specific membrane antigen (PSMA), especially 68Ga-PSMA-11, has changed the management of patients with prostate cancer (PCa). 18F-Labelled ligands can be produced in larger amounts and therefore can improve availability for a larger group of pati...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
20 July 2018
|
| In: |
European journal of nuclear medicine and molecular imaging
Year: 2018, Jahrgang: 45, Heft: 12, Pages: 2055-2061 |
| ISSN: | 1619-7089 |
| DOI: | 10.1007/s00259-018-4089-x |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1007/s00259-018-4089-x
|
| Verfasserangaben: | Kambiz Rahbar, Ali Afshar-Oromieh, Robert Seifert, Stefan Wagner, Michael Schäfers, Martin Bögemann, Matthias Weckesser |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1662462212 | ||
| 003 | DE-627 | ||
| 005 | 20230426172412.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190327s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00259-018-4089-x |2 doi | |
| 035 | |a (DE-627)1662462212 | ||
| 035 | |a (DE-599)KXP1662462212 | ||
| 035 | |a (OCoLC)1341205629 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Rahbar, Kambiz |d 1975- |e VerfasserIn |0 (DE-588)131737244 |0 (DE-627)513322949 |0 (DE-576)298707942 |4 aut | |
| 245 | 1 | 0 | |a Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer |c Kambiz Rahbar, Ali Afshar-Oromieh, Robert Seifert, Stefan Wagner, Michael Schäfers, Martin Bögemann, Matthias Weckesser |
| 246 | 3 | 3 | |a Diagnostic performance of 18 F-PSMA-1007 PET CT in patients with biochemical recurrent prostate cancer |
| 264 | 1 | |c 20 July 2018 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Im Titel ist die 18 hochgestellt | ||
| 500 | |a Gesehen am 27.03.2019 | ||
| 520 | |a PurposeThe introduction of ligands targeting prostate-specific membrane antigen (PSMA), especially 68Ga-PSMA-11, has changed the management of patients with prostate cancer (PCa). 18F-Labelled ligands can be produced in larger amounts and therefore can improve availability for a larger group of patients. The aim of this study was to evaluate the diagnostic performance of the recently introduced 18F-PSMA-1007 in patients with recurrent PCa.MethodsThis retrospective analysis included 100 consecutive patients with biochemical relapse (mean age 68.75 ± 7.6 years) referred for PSMA PET/CT. Whole-body PET/CT imaging (from the lower limbs to the skull) was performed in all patients 120 min after injection of 338 ± 44.31 MBq 18F-PSMA-1007. Prostatectomy, radiation beam therapy of the prostate bed and androgen-deprivation therapy had been performed in 92%, 45% and 27% of the patients, respectively. Radiation beam therapy of the prostate bed had been performed in addition to surgery in 38 patients (38%) and 10 patients (10%) had received all three therapy modalities. The probability of a 18F-PSMA-1007 PET/CT scan suggestive of pathology was compared with the Gleason score (GS) and PSA level.ResultsOf the 100 patients, 95 (95%) showed at least one pathological finding on 18F-PSMA-1007 PET/CT. The overall median PSA level was 1.34 ng/ml (range 0,04-41.3 ng/ml). The rates of pathological scans were 86%, 89%, 100% and 100% among patients with PSA levels ≤0.5, 0.51-1.0, 1.1-2.0 and > 2.0 ng/ml, respectively. The median GS was 7 (range 5-10). The majority of patients (70) with a GS available had a score in the range 7-9. The rate of pathological scans in these patients was 93% (65/70). The median SUVmax values of the pathological findings were 10.25, 14.32, 13.16 and 28.87 in patients with PSA levels ≤0.5, 0.51-1.0, 1.1-2.0 and >2.0 ng/ml, respectively. The median SUVmax in patients with a PSA level of >2.0 ng/ml was significantly higher than in all other PSA groups.Conclusion18F-PSMA-1007 PET/CT can detect recurrent PCa in a high percentage of patients with biochemical relapse. The probability of a pathological 18F-PSMA-1007 PET/CT scan seems to be high even in patients with a low PSA level ≤0.5 ng/ml, and this may have a significant impact on the management of this relevant group of patients. | ||
| 650 | 4 | |a Biochemical relapse | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 4 | |a PSMA-1007 | |
| 700 | 1 | |a Afshar-Oromieh, Ali |d 1975- |e VerfasserIn |0 (DE-588)130260436 |0 (DE-627)496579711 |0 (DE-576)189580003 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of nuclear medicine and molecular imaging |d Heidelberg [u.a.] : Springer-Verl., 2002 |g 45(2018), 12, Seite 2055-2061 |h Online-Ressource |w (DE-627)359787258 |w (DE-600)2098375-X |w (DE-576)110279549 |x 1619-7089 |7 nnas |a Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer |
| 773 | 1 | 8 | |g volume:45 |g year:2018 |g number:12 |g pages:2055-2061 |g extent:7 |a Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00259-018-4089-x |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00259-018-4089-x |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190327 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 130260436 |a Afshar-Oromieh, Ali |m 130260436:Afshar-Oromieh, Ali |p 2 | ||
| 999 | |a KXP-PPN1662462212 |e 3417178428 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer","title_sort":"Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer"}],"person":[{"family":"Rahbar","given":"Kambiz","roleDisplay":"VerfasserIn","display":"Rahbar, Kambiz","role":"aut"},{"display":"Afshar-Oromieh, Ali","roleDisplay":"VerfasserIn","role":"aut","family":"Afshar-Oromieh","given":"Ali"}],"titleAlt":[{"title":"Diagnostic performance of 18 F-PSMA-1007 PET CT in patients with biochemical recurrent prostate cancer"}],"recId":"1662462212","language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Im Titel ist die 18 hochgestellt","Gesehen am 27.03.2019"],"id":{"doi":["10.1007/s00259-018-4089-x"],"eki":["1662462212"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"20 July 2018"}],"name":{"displayForm":["Kambiz Rahbar, Ali Afshar-Oromieh, Robert Seifert, Stefan Wagner, Michael Schäfers, Martin Bögemann, Matthias Weckesser"]},"relHost":[{"id":{"issn":["1619-7089"],"zdb":["2098375-X"],"eki":["359787258"]},"origin":[{"publisherPlace":"Heidelberg [u.a.]","dateIssuedDisp":"2002-","publisher":"Springer-Verl.","dateIssuedKey":"2002"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"official journal of the European Association of Nuclear Medicine (EANM)","title":"European journal of nuclear medicine and molecular imaging","title_sort":"European journal of nuclear medicine and molecular imaging"}],"recId":"359787258","language":["eng"],"disp":"Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancerEuropean journal of nuclear medicine and molecular imaging","note":["Gesehen am 13.02.2023","Ungezählte Beil.: Supplement"],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"text":"45(2018), 12, Seite 2055-2061","volume":"45","extent":"7","year":"2018","issue":"12","pages":"2055-2061"},"pubHistory":["29.2002 -"]}],"physDesc":[{"extent":"7 S."}]} | ||
| SRT | |a RAHBARKAMBDIAGNOSTIC2020 | ||